Viatris To Bring In Plenty Of Brand Knowledge With New CEO Smith
Former Celgene Exec Also Brings Deals Experience
Executive Summary
Only three months after joining Viatris’ board of directors, Scott Smith, famed for spearheading Celgene’s successful and lucrative Inflammation and Immunology division, has been announced as the company’s new CEO, beginning 1 April.
You may also be interested in...
Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
Pfizer To Merge Off-Patent Business With Mylan
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
One Foot In The Door? Trio Look To Reenter Annulled EU Generic Tecfidera Market
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.